BC
COLL icon

Bridgefront Capital’s Collegium Pharmaceutical COLL Stock Holding History

Bridgefront Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,752
Closed -$231K – 644
2025
Q1 		$231K Buy
+7,752
New +$237K 0.07% 468

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bridgefront Capital's COLL Position: Q2 2025 in Review

Bridgefront Capital sold out of Collegium Pharmaceutical (COLL) in Q2 2025, closing a stake of 7,752 shares — an estimated $231K sold.

Bridgefront Capital first reported a position in COLL in Q1 2025 and held it in 1 quarter. The position peaked at $231K in Q1 2025. 223 funds tracked by Wall St. Rank hold COLL as of Q2 2025.

  • Bridgefront Capital reported no remaining Collegium Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 7,752 Collegium Pharmaceutical shares in Q2 2025, an estimated $231K.
  • Bridgefront Capital first reported a position in Collegium Pharmaceutical in Q1 2025 and held it in 1 quarter.
  • Bridgefront Capital's Collegium Pharmaceutical position peaked at $231K in Q1 2025.
  • 223 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.